Insider · CIK 0001638474
Jeffrey W. Albers
director
Files at BPMC (Blueprint Medicines Corp), SYRE (Spyre Therapeutics, Inc.), KYMR (Kymera Therapeutics, Inc.). First filing Oct 28, 2024, latest Dec 8, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 12
$0 bought, $7.0M sold
Where the trades landed
Last year at the 2 companies this insider has traded most, with each buy and sell on the bar it happened.
KYMR: Kymera Therapeutics, Inc.
KYMROct 9, 2026 · close 112.40
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
SYRE: Spyre Therapeutics, Inc.
SYREOct 9, 2026 · close 85.69
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 32Weak | Kymera Therapeutics, Inc. | $449k 5,000 shares | -100% | +348% from low0% from high | |
| 22Weak | Kymera Therapeutics, Inc. | $296k 5,000 shares | -100% | +185% from low0% from high | |
| 29Weak | Kymera Therapeutics, Inc. | $311k 6,349 shares | -100% | +107% from low-17% from high | |
| 13Weak | Blueprint Medicines Corp | $506k 5,000 shares | -3% | - | |
| 48Moderate | Blueprint Medicines Corp | $512k 5,766 shares | -4% | - | |
| 15Weak | Blueprint Medicines Corp | $659k 7,500 shares | -5% | - | |
| 20Weak | Blueprint Medicines Corp | $1.7M 15,161 shares | -9% | - | |
| 13Weak | Blueprint Medicines Corp | $511k 5,000 shares | -3% | - | |
| 20Weak | Blueprint Medicines Corp | $1.3M 15,000 shares | -9% | - | |
| 6Weak | Blueprint Medicines Corp | $510k 5,000 shares | -3% | - | |
| 13Weak | Spyre Therapeutics, Inc. | $246k 6,700 shares | -20% | - | |
| 0Weak | Spyre Therapeutics, Inc. | $11k 300 shares | -1% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 8, 2025 | KYMR Kymera Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +5,000 | $14.18 | $71k | 5,000 | Dec 8, 2025 |
| Dec 8, 2025 | KYMR Kymera Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -2,748 | $89.32 | $245k | 2,252 | Dec 8, 2025 |
| Dec 8, 2025 | KYMR Kymera Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -2,252 | $90.30 | $203k | 0 | Dec 8, 2025 |
| Dec 8, 2025 | KYMR Kymera Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -5,000 | $0.00 | $0 | 7,000 | Dec 8, 2025 |
| Oct 13, 2025 | KYMR Kymera Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +5,000 | $10.34 | $52k | 5,000 | Oct 14, 2025 |
| Oct 13, 2025 | KYMR Kymera Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -5,000 | $59.19 | $296k | 0 | Oct 14, 2025 |
| Oct 13, 2025 | KYMR Kymera Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -5,000 | $0.00 | $0 | 0 | Oct 14, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Common Stock | -5,777 | - | - | 144,755 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | UTender of shares Common Stock | -144,755 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -92,500 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -170,000 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -110,500 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -90,000 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -80,000 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -15,000 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -5,300 | - | - | 0 | Jul 21, 2025 |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | DDisposition to issuer Stock Option (Right to Buy)derivative | -4,570 | - | - | 0 | Jul 21, 2025 |
| Jun 25, 2025 | KYMR Kymera Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +16,000 | $0.00 | $0 | 16,000 | Jun 26, 2025 |
| Jun 18, 2025 | BPMC Blueprint Medicines Corp | AGrant or award Common Stock | +3,902 | $128.12 | $500k | 150,532 | Jun 24, 2025 |
| Jun 3, 2025 | KYMR Kymera Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +6,349 | $10.34 | $66k | 6,349 | Jun 3, 2025 |
| Jun 3, 2025 | KYMR Kymera Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -6,349 | $49.00 | $311k | 0 | Jun 3, 2025 |
| Jun 3, 2025 | KYMR Kymera Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -6,349 | $0.00 | $0 | 5,000 | Jun 3, 2025 |
| May 29, 2025 | SYRE Spyre Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Jun 2, 2025 |
| May 27, 2025 | BPMC Blueprint Medicines Corp | MOption exercise Common Stock10b5-1 | +5,000 | $36.05 | $180k | 151,630 | May 29, 2025 |
| May 27, 2025 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock10b5-1 | -4,350 | $101.02 | $439k | 147,280 | May 29, 2025 |
| May 27, 2025 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock10b5-1 | -650 | $101.93 | $66k | 146,630 | May 29, 2025 |
| May 27, 2025 | BPMC Blueprint Medicines Corp | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -5,000 | $0.00 | $0 | 92,500 | May 29, 2025 |
| Mar 5, 2025 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock | -5,766 | $88.80 | $512k | 146,630 | Mar 17, 2025 |
| Mar 12, 2025 | BPMC Blueprint Medicines Corp | MOption exercise Common Stock10b5-1 | +7,500 | $36.05 | $270k | 159,896 | Mar 14, 2025 |
| Mar 12, 2025 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock10b5-1 | -5,700 | $87.62 | $499k | 154,196 | Mar 14, 2025 |
| Mar 12, 2025 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock10b5-1 | -1,800 | $88.37 | $159k | 152,396 | Mar 14, 2025 |
| Mar 12, 2025 | BPMC Blueprint Medicines Corp | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -7,500 | $0.00 | $0 | 97,500 | Mar 14, 2025 |
| Jan 21, 2025 | BPMC Blueprint Medicines Corp | MOption exercise Common Stock10b5-1 | +10,000 | $36.05 | $361k | 167,557 | Jan 23, 2025 |
| Jan 21, 2025 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock10b5-1 | -7,561 | $109.11 | $825k | 159,996 | Jan 23, 2025 |
| Jan 21, 2025 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock10b5-1 | -7,400 | $109.92 | $813k | 152,596 | Jan 23, 2025 |
| Jan 21, 2025 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock10b5-1 | -200 | $110.61 | $22k | 152,396 | Jan 23, 2025 |
| Jan 21, 2025 | BPMC Blueprint Medicines Corp | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -10,000 | $0.00 | $0 | 105,000 | Jan 23, 2025 |
| Jan 13, 2025 | BPMC Blueprint Medicines Corp | MOption exercise Common Stock10b5-1 | +5,000 | $36.05 | $180k | 162,557 | Jan 15, 2025 |
| Jan 13, 2025 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock10b5-1 | -5,000 | $102.28 | $511k | 157,557 | Jan 15, 2025 |
| Jan 13, 2025 | BPMC Blueprint Medicines Corp | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -5,000 | $0.00 | $0 | 115,000 | Jan 15, 2025 |
| Dec 19, 2024 | BPMC Blueprint Medicines Corp | MOption exercise Common Stock10b5-1 | +15,000 | $36.05 | $541k | 172,557 | Dec 20, 2024 |
| Dec 19, 2024 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock10b5-1 | -3,920 | $88.28 | $346k | 168,637 | Dec 20, 2024 |
| Dec 19, 2024 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock10b5-1 | -5,180 | $89.01 | $461k | 163,457 | Dec 20, 2024 |
| Dec 19, 2024 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock10b5-1 | -3,800 | $91.15 | $346k | 159,657 | Dec 20, 2024 |
| Dec 19, 2024 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock10b5-1 | -2,100 | $91.96 | $193k | 157,557 | Dec 20, 2024 |
| Dec 19, 2024 | BPMC Blueprint Medicines Corp | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -15,000 | $36.05 | $541k | 120,000 | Dec 20, 2024 |
| Nov 7, 2024 | BPMC Blueprint Medicines Corp | MOption exercise Common Stock10b5-1 | +5,000 | $36.05 | $180k | 162,557 | Nov 12, 2024 |
| Nov 7, 2024 | BPMC Blueprint Medicines Corp | SOpen-market sale Common Stock10b5-1 | -5,000 | $102.00 | $510k | 157,557 | Nov 12, 2024 |
| Nov 7, 2024 | BPMC Blueprint Medicines Corp | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -5,000 | $0.00 | $0 | 135,000 | Nov 12, 2024 |
| Nov 6, 2024 | SYRE Spyre Therapeutics, Inc. | SOpen-market sale Common Stockindirect: By Sessions LLC10b5-1 | -6,700 | $36.76 | $246k | 27,360 | Nov 8, 2024 |
| Oct 25, 2024 | SYRE Spyre Therapeutics, Inc. | SOpen-market sale Common Stockindirect: By Sessions LLC10b5-1 | -300 | $36.43 | $11k | 34,060 | Oct 28, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.